Home Featured Page 198

Featured

Latest

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides...

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects...

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription...

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical...

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial...

Albert Labs Files US Provisional Patent Application and Proves Out Consistent...

PT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost...

MindMed Reports Full Year 2021 Financial Results and Business Highlights

EDITOR PICKS

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets...

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides...

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects...

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription...

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical...

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial...

Albert Labs Files US Provisional Patent Application and Proves Out Consistent...

PT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost...

MindMed Reports Full Year 2021 Financial Results and Business Highlights

EDITOR PICKS

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets...

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY